初次全膝关节置换术中骨内注射万古霉素可获得更优的临床结果
该回顾性研究纳入2016年5月至2023年5月间接受初次全膝关节置换术的1923膝,比较静脉注射与骨内注射万古霉素的结局,骨内组在90天、1年及2年假体周围感染发生率均显著低于静脉组,且90天内需口服抗生素的非手术伤口并发症更少,急性肾损伤发生率两组无显著差异。
要点
- 骨内注射万古霉素组90天、1年及2年假体周围感染发生率均显著低于静脉组。
- 骨内组30天和90天需口服抗生素的非手术伤口并发症发生率显著低于静脉组。
- 骨内组急性肾损伤发生率低于静脉组,但未达统计学显著差异。
核心结论
- 初次全膝关节置换术中骨内注射万古霉素较静脉注射可降低90天、1年及2年假体周围感染发生率,并减少90天内非手术伤口并发症,急性肾损伤发生率的降低未达统计学显著。
研究设计与样本
- 回顾性队列研究,纳入2016年5月至2023年5月间接受初次全膝关节置换术的1923膝,最短随访90天(平均913±611天)。
- 静脉组564膝,术前按体重给予万古霉素;骨内组1359膝,止血带充气后于胫骨近端注射500 mg万古霉素。
- 所有患者围手术期均按体重给予静脉头孢唑林;采用2018年国际共识会议标准诊断假体周围感染;急性肾损伤定义为肌酐升高0.3 mg/dL。
主要发现
- 假体周围感染发生率:骨内组 vs 静脉组在90天为0.5% vs 1.6%(P=0.018),1年为0.7% vs 1.8%(P=0.048),2年为0.9% vs 2.4%(P=0.032),骨内组均显著低于静脉组。
- 需口服抗生素的非手术伤口并发症发生率:骨内组 vs 静脉组在30天为2.3% vs 4.3%(P=0.023),90天为2.5% vs 5.4%(P=0.003),骨内组均显著低于静脉组。
- 急性肾损伤发生率:骨内组 vs 静脉组为1.6% vs 3.2%(P=0.078),差异未达统计学显著。
- 深静脉血栓、肺栓塞及手术伤口并发症的发生率两组无差异。
关键数值与推荐
- 假体周围感染诊断采用2018年国际共识会议标准。
- 急性肾损伤定义为肌酐升高0.3 mg/dL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Periprosthetic joint infection (PJI) remains a feared complication after total knee arthroplasty (TKA). This study reports updated outcomes of the incidence of PJI, adverse reactions, and complications of our cohort with increased clinical follow-up of our previous study reported in 2021. METHODS: A retrospective review of 1,923 knees that received either intravenous (IV) or intraosseous (IO) vancomycin during primary TKA between May 2016 and May 2023 with a minimum 90-day follow-up (mean 913 ± 611 days). There were 564 cases in the IV group and 1,359 in the IO group. The IV group received a weight-based dose of vancomycin before incision, and the IO group received 500 mg of vancomycin in the proximal tibia after tourniquet inflation. All patients received a weight-based dose of IV cefazolin perioperatively. The 2018 International Consensus Meeting criteria were used to diagnose PJI. Acute kidney injury (AKI) was defined as a creatinine increase of 0.3 mg/dL. RESULTS: The IO group demonstrated a significantly lower incidence of PJI compared to the IV group at 90-day (0.5 versus 1.6%, P = 0.018), 1-year (0.7 versus 1.8%, P = 0.048), and 2-year (0.9 versus 2.4%, P = 0.032) follow-up. Additionally, there was a lower incidence of nonoperative wound complications requiring oral antibiotics in the IO group at 30-day (2.3 versus 4.3%, P = 0.023) and at 90-day (2.5 versus 5.4%, P = 0.003) follow-up. There was a lower incidence of AKI in the IO group (1.6 versus 3.2%, P = 0.078), but this did not reach statistical significance. There was no difference in the incidence of deep vein thrombosis, pulmonary embolism, or operative wound complications. CONCLUSIONS: Intraosseous vancomycin demonstrated superior clinical outcomes over IV vancomycin with a reduced incidence of PJI at 90-day, 1- and 2-year follow-up after primary TKA. Additional benefits of IO vancomycin were a reduction in nonoperative wound complications through 90-day follow-up and a nonstatistically significant reduction in the incidence of AKI.
引用
- Park KJ, Wininger AE, Sullivan TC, et al. Superior Clinical Results With Intraosseous Vancomycin in Primary Total Knee Arthroplasty. J Arthroplasty. 2025. PMID: 40334953. doi:10.1016/j.arth.2025.04.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。